Valencia, Pedro MPridgen, Eric MPerea, BrianGadde, SureshSweeney, ChristopherKantoff, PhilipBander, Neil HLippard, Stephen JLanger, RobertKarnik, RohitFarokhzad, Omid2016-10-142013Valencia, Pedro M, Eric M Pridgen, Brian Perea, Suresh Gadde, Christopher Sweeney, Philip W Kantoff, Neil H Bander, et al. 2013. “Synergistic Cytotoxicity of Irinotecan and Cisplatin in Dual-Drug Targeted Polymeric Nanoparticles.” Nanomedicine 8 (5) (May): 687–698. doi:10.2217/nnm.12.134.1743-5889http://nrs.harvard.edu/urn-3:HUL.InstRepos:29010446Aim: Two unexplored aspects for irinotecan and cisplatin (I&C) combination chemotherapy are (1) actively targeting both drugs to a specific diseased cell type and (2) delivering both drugs on the same vehicle to ensure their synchronized entry into the cell at a well-defined ratio. In this work we report the use of targeted polymeric nanoparticles (NPs) to co-encapsulate and deliver I&C to cancer cells expressing the Prostate Specific Membrane Antigen (PSMA). Method: We prepared targeted NPs in a single-step by mixing four different precursors inside microfluidic devices. Results: I&C were encapsulated in 55-nm NPs and showed an 8-fold increase in internalization by PSMA-expressing LNCaP cells compared to non-targeted NPs. NPs co-encapsulating both drugs exhibited strong synergism in LNCaP cells with a combination index of 0.2. Conclusion: The strategy of co-encapsulating both irinotecan and cisplatin in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer.en-USNanoparticlesCombination ChemotherapyCisplatinIrinotecanPSMAJournal Article2016-10-1410.2217/nnm.12.134